Search is Powered by Google
Cancer / Oncology News

Normal cells in tumors may aid cancer growth

Main Category: Cancer / Oncology
Article Date: 16 Oct 2004 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Normal cells that live among the cancer cells in a tumor may not be the innocent bystanders they are usually assumed to be.

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has found that the normal cells in tumors, known collectively as the tumor stroma, may lose more regions of DNA than do the cancer cells in the course of tumor development.

When DNA is lost, the genes located in those regions are also lost.

"Cancer geneticists have looked upon the stroma as just innocent soil that passively receives the seed in which cancer grows," says Charis Eng, the Dorothy E. Klotz Chair of Cancer Research and director of the clinical cancer genetics program.

"But our study indicates that genetic damage occurs in stromal tumors cells, and that that damage may play an important role in tumor development."

The findings might help explain why tumors often behave differently, and respond differently to treatment, in people with seemingly identical cancers. The genetic changes in stromal cells also may provide new targets for future anti-cancer drugs and present a new strategy for treating and preventing cancer, says Eng, a recipient of the Doris Duke Distinguished Clinical Scientist Award.

The study is published in the Oct. 15 issue of the journal Cancer Research.

How the DNA damage occurs in stromal cells isn't yet known, but it might result from exposure to carcinogens, Eng says. It's also too soon to say how genetic damage to stromal cells might influence tumor growth.

However, stromal cells can produce growth factors and other substances that can influence the behavior of cancer cells. The loss of chromosome regions may result in the loss of genes that control these substances. Stromal cells may also produce factors that limit the growth of nearby cells. Loss of genes for such factors would remove those inhibitors and allow cancer cells to grow.

"But those are only hypotheses," Eng says. "I think that the stroma plays an important role in enabling a tumor to invade neighboring tissue and spread. If that proves to be true, someone may someday develop a drug that targets stroma cells and prevents the cancer from spreading."

Eng and her colleagues analyzed 134 tissue samples from invasive breast tumors. They examined stromal cells known as fibroblasts, the major component of the tumor stroma. Fibroblasts produce the fibrous scaffolding in tumors and normal tissues. (Stromal cells also include immune cells, fat cells and blood vessel cells.)

The investigators used 381 molecular markers scattered throughout the human genome (the entire set of human chromosomes). The markers served as signposts that identify various regions of the 46 human chromosomes.

Among the fibroblasts, the researchers found that 38 markers - or 38 regions of DNA - were lost from 19 different chromosomes. When the researchers then looked for the markers in the cancer cells, they found that 19 regions of DNA were lost from 15 different chromosomes.

This indicates that more DNA regions may be lost in a tumor's stromal cells than in its cancer cells. Furthermore, the losses were not spread randomly over the chromosomes. Instead, they were clustered in specific regions, or hotspots, on chromosomes, suggesting that they may play a role in tumor development.

The researchers are now looking for correlations between the stromal genetic damage seen in patients' tumors and how those tumors behave and respond to therapy.

Other OSU researchers involved in this study were Koichi Fukino, a postdoctoral researcher; Lei Shen, assistant professor in the School of Public Health; Satoshi Matsumoto, postdoctoral researcher; and Carl D. Morrison, assistant professor of pathology.

Funding from the V Foundation and the National Cancer Institute supported this research.

Contact: Darrell E. Ward, Medical Center Communications, 614-293-3737, or Ward-15@medctr.osu.edu.

Contact: Darrell E. Ward
Ward-15@medctr.osu.edu
614-293-3737
Ohio State University




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...